Sign In
Buy RAIN
$2.21
-0.115 (-4.96%)
At Close: Jun 03, 2026
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit
03:38pm, Friday, 08'th Sep 2023
BENSALEM, Pa. , Sept. 8, 2023 /PRNewswire/ -- Law Offices of Howard G.
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Rain Oncology Inc.(RAIN) Investors of a Class Action Lawsuit and Upcoming Deadline
05:45am, Thursday, 07'th Sep 2023
NEW YORK , Sept. 7, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit.
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit
03:56pm, Tuesday, 05'th Sep 2023
LOS ANGELES , Sept. 5, 2023 /PRNewswire/ -- The Law Offices of Frank R.
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
06:39pm, Thursday, 10'th Aug 2023
Rain Oncology Inc. (NASDAQ:RAIN ) Q2 2023 Earnings Call Transcript August 10, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Nelson Cabatuan - Acting SVP,
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
08:00am, Wednesday, 26'th Jul 2023
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and prov
Monish Pabrai on Finding Multi-Baggers and Intrinsic Valuation
04:55pm, Tuesday, 18'th Jul 2023
Mohnish Pabrai (Trades, Portfolio) is a legendary investor and the founder of Pabrai funds.
Why Shares of Rain Oncology Are Plummeting Today
03:15pm, Monday, 22'nd May 2023
Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma.
Why Is RAIN Stock Down 87% Today?
11:07am, Monday, 22'nd May 2023
Rain Oncology (NASDAQ: RAIN ) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company's Phase 3 M
Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
03:42am, Saturday, 13'th May 2023
Rain Oncology, Inc. (NASDAQ:RAIN ) Q1 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Br
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
02:36am, Thursday, 27'th Apr 2023
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data.
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
02:34pm, Wednesday, 26'th Apr 2023
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023.
Rain Oncology Inc. (RAIN) Q4 2022 Earnings Call Transcript
09:04pm, Thursday, 09'th Mar 2023
Rain Oncology Inc. (NASDAQ:RAIN ) Q4 2022 Results Conference Call March 9, 2023 5:00 PM ET Company Participants Dan Ferry - LifeSci Advisors Avanish Vellanki - Chief Executive Officer Robert Doebele -
Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference
08:00am, Tuesday, 07'th Mar 2023
NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, m
Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Virtual Conference
08:00am, Monday, 14'th Nov 2022
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead produc
Rain Therapeutics Inc. (RAIN) Q3 2022 Earnings Call Transcript
10:43pm, Saturday, 12'th Nov 2022
Rain Therapeutics Inc. (NASDAQ:RAIN ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Dan Ferry – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Rob
